8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 30, 2019

 

 

Synthorx, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-38756   46-4709185

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

11099 N. Torrey Pines Road, Suite 190

La Jolla, California

  92037
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code: (858) 750-4789

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading
Symbol(s)

 

Name of each exchange
on which registered

Common Stock, par value $0.001 per share   THOR   The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☒

 

 

 


Item 8.01

Other Matters.

On September 30, 2019, certain members of the management team of Synthorx, Inc. (the “Company”) will be presenting a poster (the “Poster”) at the European Society for Medical Oncology Congress 2019 conference. A copy of the Poster is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

 

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit
    No.    

  

Description

99.1    Poster, dated September 30, 2019.

Forward-Looking Statements

Certain statements contained in this report are forward-looking statements that involve a number of risks and uncertainties. Words such as “believe,” “may,” “will,” “estimate,” “promise,” “plan”, “continue,” “anticipate,” “intend,” “expect,” “potential” and similar expressions (including the negative thereof) are intended to identify forward-looking statements, though not all forward-looking statements necessarily contain these identifying words. For such statements, the Company claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from the Company’s expectations. Factors that could cause actual results to differ materially from those stated or implied by the Company’s forward-looking statements are disclosed in the Company’s filings with the Securities and Exchange Commission, including in the section captioned “Risk Factors” in the Company’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2019. These forward-looking statements represent the Company’s judgment as of the time of this report. The Company disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Synthorx, Inc.
Dated: September 30, 2019   By:  

/s/ Laura Shawver

    Laura Shawver, Ph.D.
    President and Chief Executive Officer
EX-99.1

Exhibit 99.1

 

 

LOGO

 

THOR-707, a Novel Not-alpha IL-2, Promotes All Key Immune System Anti-tumoral Actions of IL-2 Without Eliciting Vascular Leak Syndrome (VLS)

Marcos E. Milla; Jerod L. Ptacin; Lina Ma; Carolina E. Caffaro; Hans R. Aerni; Kristine M. San Jose; Michael J. Pena; Robert W. Herman; Yelena Pavlova; David B. Chen; Taylor Ismaili; Shukuan Li; Jasmine Nguyen; Namit Singh; Laura K. Shawver; Lilia K. Koriazova; Ingrid B. Joseph

Synthorx Inc. Research & Development, La Jolla, CA

 


LOGO


LOGO


LOGO


LOGO


LOGO